Last quote about Amgen

Carter Worth - Cornerstone Macro
What we know about biotech is it was the leading single place you could be from 2011 to 2015. This is arguably the single best-performing equity over the past 30 years. It's ready to go again, having rested for two or three years. To my eye we are going to explode out to the
share this quote
Jun 05 2017
Multiple people spoke about Amgen in the news. We gather all their quotes on this page, an easy way to see all views about this topic at a glance. To go deeper, all quotes are redirected to the article from which they come. Sean E. Harper is the person who had the greatest number of quotes. The most recent one of them is: “The efficacy results from this study comparing Evenity to an active control are robust. At the same time, the newly observed cardiovascular safety signal will have to be assessed as part of the overall benefit/risk profile for Evenity.”.
Automatically powered by Storyzy
Take our quote verification challenge and find out !
Joshua Ofman - Amgen

In fact, they may even be below the value-based range for the types of patients getting access now. We want to engage payers in risk-sharing contracts. If the drug does not perform, net prices will go down. But if the drug performs as we expect, they will not. Access restrictions have been a real challenge for patients and their

Leslie Cho - Cleveland Clinic

What I care about is there are patients for whom the PCSK9 is absolutely

Jorge Plutzky

Any statistically significant reduction in cardiovascular events would be important to

Jim Cramer

In case President Trump is watching, let me just say I am thrilled that we have such strong hiring in this country, but the fastest way to reverse that trend would be to put through this border tax and watch retailer after retailer either close stores or go out of business. Yes, it would be that

Jim Cramer

If you don't already own it, I would wait. There is always a chance that this time is different, but I know that the sell-off last time was nasty, brutish and short, and it gave you one of the best buying opportunities we have had in

Sean E. Harper - Amgen

Endeavor is the only (relapsed multiple myeloma) study to demonstrate a survival benefit in a head-to-head comparison with a current standard of care

Ying Huang

In light of Trump's proposal on cash repatriation, we believe AMGN could repatriate a significant portion of its $34.8B cash held overseas. The potential share buyback, dividend payment and acquisitions associated with the cash repatriation can further boost stock performance, in our

Richard Francis - Sandoz

[The legal fight] won't really reach a conclusion until 2018. That's the frustration sometimes of the legal situation, but the way I look at that, we're carving the landscape out as we

Len Schleifer - Regeneron Pharmaceuticals

To say that you cannot wait, is that putting patients first? It's no small wonder that our industry isn't

Len Schleifer - Regeneron Pharmaceuticals

If this industry is to survive, we have got to do the right thing by patients … and still adequately reward our

Len Schliefer

To say that you cannot wait, is that putting patients first? It's no small wonder that our industry isn't beloved. If this industry is to survive, we have got to do the right thing by patients ... and still adequately reward our

Jim Cramer

I think Amgen can go much higher, perhaps on comments coming out of this healthcare

Michael Yee - RBC Capital Markets

If Praluent was gone from the market the long-term peak sales for Repatha could move from $2 billion to $3 billion to $4 billion worldwide, in

Karen Linehan - Sanofi

We will immediately appeal today's ruling, along with the jury's earlier finding upholding the validity of Amgen's patents. It is our longstanding position that Amgen's patent claims are invalid and that the best interests of patients will be greatly disserved by an injunction preventing access to

Kristen Davis - Amgen

The court's ruling today is an important step in this case and confirms the jury's finding that the patents which protect Repatha are valid and infringed by

Ashleigh Koss - Sanofi

It is our longstanding position that Amgen's asserted patent claims are invalid, and we intend to appeal today's

Randy Shultz

We've got 13 million candidate patients ... and at least initially there will be four drugs addressing what is five times as many patients (as the RA market). We would argue that each of these drugs has the potential to be a blockbuster alongside each

Charles Duncan - Piper Jaffray

Migraine today can be characterized as similar to RA in the past, in that it's a large but under-treated, and also under-diagnosed, market. The burden of disease in terms of patient quality of life, function, and resource utilization is also high. Because of these market dynamics, there is likely room for multiple agents - even of the same mechanism - to be

Stephen Nicholls

These findings suggest that the large clinical outcome trials currently underway are likely to show major

Seth Baum

It's crazy what's going on. They've basically destroyed our capacity to treat our patients with the drugs that we need to treat them

Steven Nissen - Cleveland Clinic

That's unbelievable. So when you get down to 24 you've got a really high chance of your plaques melting

Steven Nissen - Cleveland Clinic

We didn't know what would happen to disease progression at LDL cholesterol levels when we go to below about

Richard Francis - Sandoz

The realization of what it's going to take to stay in this market and be successful has led to a change in the landscape and the players in

Michael Nawrath

It's not like these companies are bitter enemies. These court cases are simply the last resort of original drug makers to wring a few more months or a year of exclusivity from their

Vasant Narasimhan - Novartis

Our focus has been continuing to generate the data and convince physicians that it's worth making the switch. Now you have data out to four years showing we've maintained the efficacy, at the levels that we saw after year

Andrzej Jakubowiak

This was the wrong combination chosen for this evaluation, wrong duration of treatment as well, which we now know and is potentially

Vasant Narasimhan - Novartis

These important data further support the efficacy of AMG 334 in patients who currently have limited therapeutic

Carol Lynch - Novartis

We are committed to bringing Erelzi to the U.S. market as soon as

David Seaburg - Cowen and Company

We are seeing something occur very different on the desk here. We're seeing people versus selling every rally, or shorting every rally, coming in now and buying every dip. We're seeing a big sentiment shift in general; people getting very comfortable, and that's mainly right after a lot of big-cap names have reported good quarters, decent

Chad Morganlander

We believe that you're going to see consistent revenue growth, as well as improvement within operating margins over the next three to five

Sean E. Harper - Amgen

Migraine is the sixth leading cause of disability worldwide. Three to seven million Americans spend more than half of each month living with the debilitating symptoms of chronic

Tim Race - Deutsche Bank

A permanent injunction is unlikely. However, the likelihood of settlement has now increased substantially with Sanofi and its partner Regeneron potentially forced to pay

Jay Siegel

Only direct clinical comparisons of (Remsima) and Remicade in active irritable bowel disease can provide the requisite

Robert A. Bradway - Amgen

We remain on track to meet or exceed our 2018 commitments and deliver value for patients and

No quotes...
|< <
> >|

Quotes about Amgen

Quote Verifier
Check if the quote you read on social networks is authentic
This webpage has been created by a robot: errors and absent quotes cannot be totally avoided

Quote :

Mistake :

Comments :